Reaction
Periodontal Disease reporting signals
As of the last recalculation, Periodontal Disease appears in 1,389 FAERS reports alongside 21 co-occurring drug terms. The strongest observed disproportionality signal is ALENDRONATE SODIUM (PRR 56.5).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Alendronate Sodium | 300 | 56.5 | 56.7 |
| Chlorhexidine Gluconate | 25 | 41.7 | 41.8 |
| Risedronate Sodium | 64 | 32.3 | 32.4 |
| Exemestane | 26 | 18.5 | 18.5 |
| Zoledronic Acid | 45 | 17.3 | 17.3 |
| Anastrozole | 31 | 12.9 | 12.9 |
| Bicalutamide | 13 | 12.9 | 12.9 |
| Buprenorphine Hydrochloride, Naloxone Hydrochloride | 20 | 12.6 | 12.6 |
| Raloxifene Hydrochloride | 12 | 12.4 | 12.4 |
| Fulvestrant | 25 | 11.5 | 11.5 |
| Gefitinib | 6 | 10.0 | 10.0 |
| Thalidomide | 24 | 10.0 | 10.0 |
| Elvitegravir, Cobicistat, Emtricitabine, And Tenofovir Disoproxil Fumarate | 5 | 8.3 | 8.4 |
| Denosumab | 89 | 7.0 | 7.0 |
| Aflibercept | 10 | 4.8 | 4.8 |
| Elvitegravir, Cobicistat, Emtricitabine, And Tenofovir Alafenamide | 3 | 4.5 | 4.5 |
| Fam-Trastuzumab Deruxtecan-Nxki | 3 | 4.5 | 4.5 |
| Romosozumab-Aqqg | 4 | 4.4 | 4.4 |
| Emtricitabine And Tenofovir Disoproxil Fumarate | 13 | 4.3 | 4.3 |
| Atezolizumab | 11 | 4.3 | 4.3 |
| Emtricitabine And Tenofovir Alafenamide | 3 | 4.0 | 4.0 |